1
Stéphane De Lombaert
BARTOLOZZI Alessandra, BOSANAC Todd, CHEN Zhidong, DE LOMBAERT Stéphane, HUBER John D, LIU Weimin, LO Ho Yin, LOKE Pui Leng, RIETHER Doris, TYE Heather, WU Lifen, ZINDELL Renee M: INHIBITEURS OXADIAZOLE DE PRODUCTION DE LEUCOTRIÈNES, OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION. BOEHRINGER INGELHEIM INTERNATIONAL, BARTOLOZZI Alessandra, BOSANAC Todd, CHEN Zhidong, DE LOMBAERT Stéphane, HUBER John D, LIU Weimin, LO Ho Yin, LOKE Pui Leng, RIETHER Doris, TYE Heather, WU Lifen, ZINDELL Renee M, MORRIS Michael P, March 29, 2012: WO/2012/040137

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases an ...


2

3
Bartolozzi Alessandra, Campbell Stewart, Cole Bridget, Ellis James, Foudoulakis Hope, Kirk Brian, Ram Siya, Sweetnam Paul, Hauer Jensen Martin, Boerma Marjan, Wang Junru, Fu Qiang: Rho kinase inhibitors. Surface Logix, Bartolozzi Alessandra, Campbell Stewart, Cole Bridget, Ellis James, Foudoulakis Hope, Kirk Brian, Ram Siya, Sweetnam Paul, Hauer Jensen Martin, Boerma Marjan, Wang Junru, Fu Qiang, CASSON Lawrence P, May 8, 2008: WO/2008/054599 (28 worldwide citation)

The present invention relates to inhibitors of ROCKl and R0CK2, which may be selective for R0CK2, and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and/or R0CK2. Also provided are treatments combining inhi ...


4
BARTOLOZZI ALESSANDRA: Compounds which selectively modulate the cb2 receptor. BOEHRINGER INGELHEIM INTERNATIONAL, Morris Michael P, December 23, 2010: WO/2010/147792 (24 worldwide citation)

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.


5
Bartolozzi Alessandra, Campbell Stewart, Foudoulakis Hope, Kirk Brian, Ram Siya, Sweetnam Paul: Pharmacokinetically improved compounds. Surface Logix, Bartolozzi Alessandra, Sweetnam Paul, LAVENUE Teresa A, October 5, 2006: WO/2006/105081 (18 worldwide citation)

The present invention relates to inhibitors of ROCKl and R0CK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and or R0CK2 that are useful for the treatment of disease.


6
Bartolozzi Alessandra, Campbell A, Foudoulakis Hope, Kim Enoch, Sweetnam Paul, Yang Yingfei: Inhibitors of microsomal triglyceride transfer protein and apo-b secretion. Surface Logix, Bartolozzi Alessandra, Campbell A, Foudoulakis Hope, Kim Enoch, Sweetnam Paul, Yang Yingfei, RUSSETT Mark, October 26, 2006: WO/2006/113910 (12 worldwide citation)

The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lower ...


7

8
BARTOLOZZI ALESSANDRA: Compounds which modulate the cb2 receptor. BOEHRINGER INGELHEIM INTERNATIONAL, Morris Michael P, July 21, 2011: WO/2011/088015 (3 worldwide citation)

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.


9
BARTOLOZZI ALESSANDRA: Compounds which selectively modulate the cb2 receptor. BOEHRINGER INGELHEIM INTERNATIONAL, Morris Michael P, March 31, 2011: WO/2011/037795 (1 worldwide citation)

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.


10
BARTOLOZZI ALESSANDRA: Heterocyclic compounds which modulate the cb2 receptor. BOEHRINGER INGELHEIM INTERNATIONAL, Morris Michael P, August 26, 2010: WO/2010/096371 (1 worldwide citation)

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.